DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Novartis
National Institutes of Health Clinical Center (CC)
Yale University
NRG Oncology
University of Florida
Hoffmann-La Roche
City of Hope Medical Center
Duke University
Cambridge University Hospitals NHS Foundation Trust
Yale University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
Masonic Cancer Center, University of Minnesota
Yale University
National Cancer Institute (NCI)